Dice Therapeutics rises after Stifel initiates coverage with 'buy'

Dice Therapeutics

07/09/2022 18:18

** Oral therapeutics developer DICE Therapeutics Inc shares
 DICE.O  rise 7.5% to $20.37 after Stifel initiates coverage
with 'buy' rating and PT of $37
    ** Stifel believes co "has a shot at becoming a major player
within the next-gen oral immunology space"
    ** Says co's lead candidate, DC–806, shares similar
mechanism as mega-blockbuster drug Cosentyx, and if approved,
DC-806 can touch sales of $3.1 bln 
    ** All 5 brokerages covering DICE, rate the stock "buy" or
higher; their median PT is $40
    

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))